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Glycogen storage disease (GSD) type Ib is caused by the deficiency of glucose-6-
phosphate translocase activity. The elder brother of the proband died at age 20 
months, and GSD Ia, a disease caused by the deficiency of glucose-6-phosphatase, 
was the diagnosis. The proband developed hypoglycemia shortly after birth. Dietary 
therapy was instituted immediately, but his growth was poor and there were 
repeated episodes of pyogenic infection. Neutropenia had been observed since 6 
months of age, but the diagnosis of GSD Ib was established only at 18 months of age 
after two mutations (c.354_355insC (p. W118fsX12) and c.736T > C (p.W246R)) were 
detected on his SLC37A4 gene. Regular administration of G-CSF rapidly improved 
his health and decreased his hospital stay. Although GSD Ib is very rare in Taiwan, 
correct diagnosis is essential to save the lives of such patients.
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1. Introduction
Type I glycogen storage disease (GSD) represents a 
group of autosomal recessive disorders that present 
with growth retardation, hepatomegaly, hypogly-
cemia, lactic acidosis, hyperlipidemia and hyperuri-
cemia.1 GSD type Ia (OMIN 232200), or von Gierke 
Disease, is caused by deficiencies in glucose-6-
phosphateatase (G6Pase) (EC 3.1.3.9) activity in 
the liver, kidney and intestinal mucosa. GSD type Ib 
(OMIN 232220) is caused by deficiencies in glucose-
6-phosphate translocase, which leads to defective 
transport of glucose-6-phosphotate from the cyto-
plasm into the lumen of the endoplasmic reticulum. 
Patients with GSD type Ib are unable to liberate 
glucose from glucose-6-phosphate, which is similar 
to patients with GSD type Ia. 
Patients with GSD Ia or Ib need uncooked corn-
starch to maintain their blood sugar.2 If treated 
adequately, normal growth can be achieved,1 and 
biochemical abnormalities such as the elevation of 
lactate, cholesterol, and triglyceride decrease, and 
the risk for liver adenoma3 or proximal renal tubular 
dysfunction is reduced.1 Liver transplantation may 
serve as an alternative treatment, which corrects the 
biochemical abberations, but long-term prognosis for 
the kidney is still unknown.
Neutropenia and impaired neutrophil function 
lead to recurrent bacterial infections and ulcera-
tion of the oral and intestinal mucosa in GSD Ib. 
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The exact mechanism for these symptoms is un-
clear, but increased apoptosis of neutrophils has 
been demonstrated.4 Granulocyte colony-stimulation 
factor (G-CSF) therapy was shown to increase the 
neutrophil number, decrease the frequency and 
severity of bacterial infections, and improve the 
chronic inflammatory bowel disease in GSD Ib.5 How-
ever, long-term benefits of G-CSF therapy have not 
been established.6 
Although GSD Ib represents one-fifth to one-sixth 
of all cases of GSD I in other countries,1 no such cases 
have been reported in Taiwan, whereas 18 cases of 
GSD Ia have been reported.7 
2. Case Report
A 3-year-old boy came to our hospital at 1 month 
of age because of acute bronchiolitis and poor ac-
tivity. The parents denied consanguinity, but his 
elder brother had been diagnosed as having GSD I 
and died at 20 months of age. Physical examina-
tion of the proband revealed mild hepatomegaly; 
laboratory tests revealed elevated levels of liver 
enzymes (aspartate aminotransferase, 119 IU/mL; 
alanine aminotransferase, 69 IU/mL), hyperlipidemia 
(triglyceride, 338 mg/dL; cholesterol, 114 mg/dL) and 
lactic acidosis (6.95 mmol/L). The patient developed 
hypoglycemia after fasting for 4 hours, and he showed 
no response in blood sugar levels to glucagon injec-
tion. Liver biopsy revealed large hepatocytes with 
empty cytoplasm. The diagnosis in this case was ini-
tially GSD Ia, although screening of the glucose-
6-phosphatase gene mutation hotspot R83H (327G > A) 
and 727G > T was negative.7
Frequent feeding was immediately instructed 
and, from 14 months of age, uncooked corn starch 
was administered at a dose of 2.0 g/kg/meal every 
4 hours. However, the patient’s growth remained 
poor, and there were repeated episodes of pyogenic 
skin infection with abscess formation. Although neu-
tropenia was observed when he was 6 months old, 
the diagnosis of GSD Ib was only established at 18 
months of age when two mutations, c.354_355insC 
(p. W118fsX12), a known disease-causing mutation, 
and c.736T > C(p.W246R), a novel mutation, were 
detected on his SLC37A4 gene. The W118fsX12 mu-
tation was inherited from his father and the W246R 
mutation was from his mother. The W246R mutation 
has not been reported previously, but it occurs on 
an evolutionarily conserved residue (Figure 1). We 
did not measure the translocase activity because 
there no laboratories were able to provide this test. 
The patient’s lymphocyte number and immunoglob-
ulin level were both normal. The nitroblue tetra-
zolium test showed normal neutrophil phagocytic 
function.
Regular G-CSF (FILGRASTIM 75 μg twice weekly) 
was administered thereafter. Although the patient 
still had frequent fevers due to acute diarrhea dur-
ing the 18 months of G-CSF therapy, his hospital 
stays decreased significantly, from 13 times (77 
days) before treatment to six times (34 days) after 
treatment (p < 0.001). His absolute neutrophil count 
increased (Figure 2A) and liver function improved 
(Figure 2B), and the patient was able to gain weight 
(Figures 2C and 2D). 
3. Discussion
To our knowledge, there is only one previous report 
of GSD Ib in the Chinese population.8 The glucose-
6-phosphate translocase gene (SLC37A4) is com-
posed of nine exons, and more than 70 mutations 
have been identified.9 The W118fsX12 mutation in 
our case has been described in German patients.10 
The W246R mutation has not been reported previ-
ously, but it occurs on an evolutionarily conserved 
residue. 
Patients with GSD-1b almost always have neutro-
penia, although it can occur at a later age.11,12 The 
mechanism responsible for the onset of neutropenia 
in GSD Ib is unclear, but patients have been treated 
successfully with G-CSF since 1989.13 G-CSF induces 
the proliferation of granulocyte progenitors, and 
triggers differentiation into mature granulocytes to 
enable chemotaxis, adhesion, phagocytosis, super-
oxide production, and antibody-dependent cell-
mediated cytotoxicity, although G-CSF may not rescue 
neutrophils from apoptosis.4 Complications of G-CSF 
therapy include splenomegaly,6 acute myelocytic 
leukemia,14 renal carcinoma,15 and osteopenia,6 but 
none of these were observed in our case.
Liver function improved after G-CSF therapy in 
our case. Elevation of liver enzymes is a common 
symptom in both GSD Ia and Ib. Improvements in 
liver function indicate improved metabolic con-
trol, and that the liver is less affected by excessive 
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Figure 1 The W246R mutation is located in an evolu-
tionarily conserved region.
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storage of glycogens and lipids. Therefore, the ad-
ministration of G-CSF not only restores myeloid 
functions13 to decrease life-threatening infections, 
but also decreases the incidence of metabolic cri-
ses. Therefore, good dietary therapy, including con-
tinuous nasogastric infusion of glucose16 or frequent 
oral administration of uncooked cornstarch,17 can 
correct the loss of glucose homeostasis. Even though 
there was no consensus on G-CSF therapy for GSD 
Ib in the ESGSD study,11 our case showed the ben-
efit of G-CSF therapy.
Long-term prognosis of GSD Ib is not good.18 
Metabolic control is often adversely affected by 
infection.1 Liver transplantation in GSD Ib has been 
successful,19 and an improvement in neutropenia 
after transplantation has been reported.19,20 Early 
diagnosis and prompt treatment are certainly the 
most critical factors in determining the prognosis 
of GSD Ib. 
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